Concepts (198)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lung Neoplasms | 40 | 2024 | 13102 | 2.200 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 26 | 2024 | 5221 | 2.090 |
Why?
|
Receptor Protein-Tyrosine Kinases | 8 | 2022 | 1660 | 1.150 |
Why?
|
Small Cell Lung Carcinoma | 4 | 2020 | 388 | 0.850 |
Why?
|
Dermatitis | 1 | 2019 | 197 | 0.610 |
Why?
|
Fellowships and Scholarships | 3 | 2022 | 1076 | 0.590 |
Why?
|
Medical Oncology | 7 | 2024 | 2265 | 0.580 |
Why?
|
Protein Kinase Inhibitors | 13 | 2023 | 5535 | 0.580 |
Why?
|
Gene Rearrangement | 3 | 2017 | 1179 | 0.560 |
Why?
|
Career Choice | 1 | 2022 | 744 | 0.560 |
Why?
|
Feedback | 2 | 2017 | 795 | 0.560 |
Why?
|
Genes, erbB-1 | 1 | 2017 | 161 | 0.550 |
Why?
|
Mutation | 18 | 2023 | 29786 | 0.460 |
Why?
|
Hematology | 3 | 2022 | 221 | 0.450 |
Why?
|
Molecular Targeted Therapy | 7 | 2018 | 2727 | 0.400 |
Why?
|
Immunotherapy | 2 | 2019 | 4445 | 0.390 |
Why?
|
Adenocarcinoma | 8 | 2018 | 6364 | 0.380 |
Why?
|
Pyrazoles | 3 | 2017 | 1972 | 0.370 |
Why?
|
Protein-Tyrosine Kinases | 4 | 2017 | 2455 | 0.350 |
Why?
|
Pyridines | 3 | 2017 | 2825 | 0.330 |
Why?
|
Antineoplastic Agents | 10 | 2021 | 13695 | 0.330 |
Why?
|
Proto-Oncogene Proteins | 4 | 2017 | 4554 | 0.280 |
Why?
|
Exons | 3 | 2023 | 2437 | 0.280 |
Why?
|
Cancer Vaccines | 1 | 2013 | 1023 | 0.270 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 4 | 2019 | 11524 | 0.270 |
Why?
|
Students, Medical | 1 | 2016 | 1862 | 0.230 |
Why?
|
Mutagenesis, Insertional | 2 | 2021 | 655 | 0.200 |
Why?
|
Drug Resistance, Neoplasm | 6 | 2019 | 5172 | 0.200 |
Why?
|
Humans | 54 | 2024 | 744343 | 0.190 |
Why?
|
Carbazoles | 2 | 2022 | 226 | 0.190 |
Why?
|
ras-GRF1 | 1 | 2020 | 26 | 0.190 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 1 | 2024 | 260 | 0.180 |
Why?
|
Quinazolinones | 1 | 2021 | 221 | 0.180 |
Why?
|
Ethylnitrosourea | 1 | 2019 | 51 | 0.180 |
Why?
|
Palliative Care | 2 | 2021 | 3493 | 0.180 |
Why?
|
Internship and Residency | 2 | 2017 | 5788 | 0.180 |
Why?
|
Alkylating Agents | 1 | 2019 | 139 | 0.170 |
Why?
|
Precursor Cells, B-Lymphoid | 1 | 2019 | 98 | 0.170 |
Why?
|
Brain Neoplasms | 3 | 2021 | 8863 | 0.160 |
Why?
|
Disease-Free Survival | 4 | 2017 | 6895 | 0.150 |
Why?
|
Survival Rate | 4 | 2021 | 12788 | 0.150 |
Why?
|
Acrylamides | 1 | 2019 | 255 | 0.150 |
Why?
|
Education, Distance | 1 | 2021 | 251 | 0.150 |
Why?
|
Anemia, Hemolytic, Autoimmune | 1 | 2019 | 142 | 0.150 |
Why?
|
Organophosphorus Compounds | 1 | 2018 | 215 | 0.150 |
Why?
|
Treatment Outcome | 10 | 2020 | 63114 | 0.140 |
Why?
|
DNA Mutational Analysis | 4 | 2018 | 4186 | 0.140 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2017 | 224 | 0.130 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2018 | 434 | 0.130 |
Why?
|
Education, Medical, Graduate | 3 | 2022 | 2291 | 0.130 |
Why?
|
Genetic Testing | 2 | 2019 | 3444 | 0.130 |
Why?
|
Mutagenesis | 1 | 2019 | 1266 | 0.130 |
Why?
|
Female | 26 | 2024 | 380194 | 0.120 |
Why?
|
Immunoconjugates | 1 | 2022 | 901 | 0.120 |
Why?
|
Gene Amplification | 2 | 2017 | 1063 | 0.120 |
Why?
|
Proto-Oncogene Proteins c-met | 2 | 2015 | 578 | 0.120 |
Why?
|
Oncogene Proteins, Fusion | 2 | 2020 | 1581 | 0.120 |
Why?
|
Aniline Compounds | 1 | 2019 | 986 | 0.120 |
Why?
|
Hepatitis B | 1 | 2020 | 695 | 0.120 |
Why?
|
Bethanechol | 1 | 2014 | 13 | 0.120 |
Why?
|
Malacoplakia | 1 | 2014 | 15 | 0.120 |
Why?
|
Piperidines | 2 | 2022 | 1602 | 0.120 |
Why?
|
Protein Interaction Domains and Motifs | 1 | 2016 | 474 | 0.120 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2017 | 2649 | 0.120 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2018 | 602 | 0.110 |
Why?
|
Hemoglobins | 1 | 2019 | 1534 | 0.110 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2017 | 890 | 0.110 |
Why?
|
Neoplasm Staging | 4 | 2021 | 11031 | 0.110 |
Why?
|
Middle Aged | 16 | 2021 | 213383 | 0.110 |
Why?
|
Specimen Handling | 1 | 2017 | 694 | 0.100 |
Why?
|
Drug Administration Schedule | 1 | 2020 | 4933 | 0.100 |
Why?
|
DNA, Neoplasm | 1 | 2017 | 1758 | 0.100 |
Why?
|
Germ-Line Mutation | 1 | 2019 | 1788 | 0.100 |
Why?
|
Aged | 15 | 2021 | 163280 | 0.100 |
Why?
|
Retrospective Studies | 9 | 2020 | 77449 | 0.100 |
Why?
|
PTEN Phosphohydrolase | 1 | 2017 | 1142 | 0.100 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2015 | 332 | 0.090 |
Why?
|
HIV | 1 | 2018 | 1604 | 0.090 |
Why?
|
Aged, 80 and over | 7 | 2021 | 57776 | 0.090 |
Why?
|
Ascorbic Acid | 1 | 2014 | 651 | 0.090 |
Why?
|
Alternative Splicing | 1 | 2015 | 1117 | 0.090 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2020 | 2942 | 0.090 |
Why?
|
Genetic Association Studies | 1 | 2019 | 2703 | 0.090 |
Why?
|
Hepatitis C | 1 | 2020 | 1591 | 0.090 |
Why?
|
Male | 19 | 2022 | 350118 | 0.080 |
Why?
|
Faculty, Medical | 1 | 2017 | 1181 | 0.080 |
Why?
|
Neoplasms | 2 | 2019 | 21683 | 0.080 |
Why?
|
Statistics, Nonparametric | 1 | 2015 | 2886 | 0.080 |
Why?
|
Fatal Outcome | 3 | 2020 | 1850 | 0.080 |
Why?
|
Genomics | 3 | 2019 | 5720 | 0.080 |
Why?
|
Renal Insufficiency | 1 | 2014 | 804 | 0.080 |
Why?
|
Receptor, erbB-2 | 1 | 2017 | 2416 | 0.080 |
Why?
|
Curriculum | 2 | 2017 | 3605 | 0.070 |
Why?
|
Kaplan-Meier Estimate | 2 | 2015 | 6538 | 0.070 |
Why?
|
Immunohistochemistry | 2 | 2018 | 11366 | 0.070 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2017 | 2948 | 0.070 |
Why?
|
Survival Analysis | 1 | 2019 | 10252 | 0.070 |
Why?
|
Pyrimidines | 1 | 2018 | 2942 | 0.070 |
Why?
|
Pneumonia | 1 | 2018 | 2133 | 0.070 |
Why?
|
Genetic Predisposition to Disease | 2 | 2019 | 17446 | 0.070 |
Why?
|
Antigens, Neoplasm | 1 | 2013 | 1988 | 0.070 |
Why?
|
Education, Medical | 1 | 2016 | 1721 | 0.060 |
Why?
|
Delivery of Health Care | 1 | 2022 | 5319 | 0.060 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2020 | 4034 | 0.060 |
Why?
|
Renal Dialysis | 1 | 2014 | 1786 | 0.060 |
Why?
|
Time Factors | 3 | 2021 | 40075 | 0.060 |
Why?
|
Patient Selection | 1 | 2015 | 4215 | 0.060 |
Why?
|
Cells, Cultured | 1 | 2019 | 19229 | 0.060 |
Why?
|
Clinical Trials as Topic | 2 | 2022 | 7913 | 0.060 |
Why?
|
Membrane Proteins | 1 | 2020 | 7880 | 0.060 |
Why?
|
Predictive Value of Tests | 2 | 2016 | 15076 | 0.050 |
Why?
|
Adult | 9 | 2021 | 214055 | 0.050 |
Why?
|
Membrane Glycoproteins | 1 | 2013 | 3768 | 0.050 |
Why?
|
Quality of Life | 1 | 2024 | 12804 | 0.050 |
Why?
|
Pandemics | 1 | 2022 | 8388 | 0.050 |
Why?
|
Caregivers | 1 | 2013 | 2094 | 0.050 |
Why?
|
Neoplasm Proteins | 1 | 2013 | 3703 | 0.050 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2019 | 3557 | 0.050 |
Why?
|
Cohort Studies | 2 | 2021 | 40561 | 0.050 |
Why?
|
Mice | 4 | 2021 | 81183 | 0.050 |
Why?
|
Smoking | 1 | 2017 | 8987 | 0.040 |
Why?
|
Videoconferencing | 1 | 2021 | 195 | 0.040 |
Why?
|
Camptothecin | 1 | 2022 | 576 | 0.040 |
Why?
|
Republic of Korea | 1 | 2020 | 539 | 0.040 |
Why?
|
Chromosomal Instability | 1 | 2019 | 184 | 0.040 |
Why?
|
Kidney | 1 | 2014 | 7186 | 0.040 |
Why?
|
Phenotype | 1 | 2015 | 16365 | 0.040 |
Why?
|
Prognosis | 4 | 2021 | 29063 | 0.040 |
Why?
|
Amino Acids | 1 | 2023 | 1736 | 0.040 |
Why?
|
Phthalazines | 1 | 2019 | 363 | 0.040 |
Why?
|
Antibodies, Monoclonal | 1 | 2013 | 9274 | 0.040 |
Why?
|
Breast Neoplasms | 1 | 2024 | 20822 | 0.040 |
Why?
|
Cell Line, Tumor | 3 | 2018 | 16689 | 0.030 |
Why?
|
Videotape Recording | 1 | 2017 | 352 | 0.030 |
Why?
|
Pleural Neoplasms | 1 | 2021 | 607 | 0.030 |
Why?
|
Animals | 4 | 2021 | 168757 | 0.030 |
Why?
|
Adrenal Gland Neoplasms | 1 | 2021 | 740 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2018 | 10943 | 0.030 |
Why?
|
ras Proteins | 1 | 2020 | 1060 | 0.030 |
Why?
|
Education | 1 | 2017 | 543 | 0.030 |
Why?
|
Autopsy | 1 | 2018 | 1020 | 0.030 |
Why?
|
Watchful Waiting | 1 | 2018 | 492 | 0.030 |
Why?
|
Muscarinic Agonists | 1 | 2014 | 87 | 0.030 |
Why?
|
Pancreatic Neoplasms | 1 | 2011 | 5256 | 0.030 |
Why?
|
Oncogenes | 1 | 2019 | 1265 | 0.030 |
Why?
|
Etoposide | 1 | 2015 | 641 | 0.030 |
Why?
|
Lymphatic Metastasis | 1 | 2021 | 2924 | 0.030 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2018 | 1375 | 0.030 |
Why?
|
MAP Kinase Signaling System | 1 | 2020 | 1526 | 0.030 |
Why?
|
Tumor Burden | 1 | 2018 | 1915 | 0.030 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2021 | 3479 | 0.030 |
Why?
|
Workflow | 1 | 2017 | 847 | 0.030 |
Why?
|
Carboplatin | 1 | 2015 | 801 | 0.030 |
Why?
|
Fluoroquinolones | 1 | 2014 | 310 | 0.030 |
Why?
|
HIV Infections | 1 | 2018 | 16718 | 0.030 |
Why?
|
Kidney Function Tests | 1 | 2014 | 684 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2022 | 2728 | 0.020 |
Why?
|
Genomic Instability | 1 | 2015 | 695 | 0.020 |
Why?
|
Disease Models, Animal | 2 | 2021 | 18029 | 0.020 |
Why?
|
Smad4 Protein | 1 | 2011 | 163 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2021 | 4851 | 0.020 |
Why?
|
Teaching | 1 | 2017 | 1174 | 0.020 |
Why?
|
Amino Acid Sequence | 1 | 2021 | 13815 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2019 | 2107 | 0.020 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2017 | 1692 | 0.020 |
Why?
|
Piperazines | 1 | 2019 | 2488 | 0.020 |
Why?
|
Program Evaluation | 1 | 2017 | 2488 | 0.020 |
Why?
|
Organ Size | 1 | 2014 | 2252 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 3 | 2018 | 20129 | 0.020 |
Why?
|
Bone Neoplasms | 1 | 2021 | 2529 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2020 | 3597 | 0.020 |
Why?
|
Urinary Tract Infections | 1 | 2014 | 788 | 0.020 |
Why?
|
Cell Line | 1 | 2021 | 15997 | 0.020 |
Why?
|
Computational Biology | 1 | 2019 | 3521 | 0.020 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2017 | 2938 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2017 | 5078 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2019 | 3528 | 0.020 |
Why?
|
Prospective Studies | 2 | 2021 | 53288 | 0.020 |
Why?
|
Antioxidants | 1 | 2014 | 1663 | 0.020 |
Why?
|
Cell Survival | 1 | 2015 | 5882 | 0.020 |
Why?
|
Liver Neoplasms | 1 | 2021 | 4253 | 0.020 |
Why?
|
Phosphorylation | 1 | 2015 | 8436 | 0.020 |
Why?
|
Genetic Variation | 1 | 2019 | 6544 | 0.010 |
Why?
|
Radiography | 1 | 2015 | 7023 | 0.010 |
Why?
|
Communication | 1 | 2017 | 3749 | 0.010 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2017 | 3923 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2018 | 6234 | 0.010 |
Why?
|
Biopsy | 1 | 2014 | 6756 | 0.010 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2019 | 9239 | 0.010 |
Why?
|
Genotype | 1 | 2015 | 12951 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2017 | 7279 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2014 | 12959 | 0.010 |
Why?
|
Disease Progression | 1 | 2015 | 13284 | 0.010 |
Why?
|
Substance-Related Disorders | 1 | 2014 | 4258 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2018 | 39050 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2014 | 7181 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2011 | 21746 | 0.010 |
Why?
|
Adolescent | 1 | 2019 | 85781 | 0.010 |
Why?
|
Concepts
(198)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(80)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_